Clinical Trials

Are you an adult with atrial fibrillation? In this study, researchers are comparing a continuous direct oral anticoagulation (DOAC) use versus time-limited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) for persons with atrial fibrillation and a moderate risk of stroke. Participants must be between the ages of 22 and 85 and have a history of atrial fibrillation. The study is taking place at locations in California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Texas, Virginia, Wisconsin, and Washington, D.C.

Did you develop atrial fibrillation after coronary artery bypass graft (CABG) surgery? Did you develop atrial fibrillation after a coronary artery bypass grafting (CABG) surgery? This study is looking at how well oral anticoagulation medicines work to prevent complications, such as blood clots and heart attack, for patients who experience post-operative atrial fibrillation (POAF). This study is in multiple locations around the country.

Does your infant have a low platelet count? This study investigates immature platelet counts as a marker for bleeding risk in newborns with thrombocytopenia, compared with platelet counts alone. Immature platelets are the most recently produced platelets and may be a better marker of platelet production. To participate in this study, you must have a newborn who is less than 32 weeks’ gestational age, has a birth weight greater than 500 grams, and has a platelet count less than 100 × 109/L. This study takes place in multiple locations in the United States, the Netherlands, and Sweden.

Are you an adult with polycythemia vera or thrombocytosis? This study aims to find a new treatment or cure for polycythemia vera and thrombocytosis by locating genes and their changes, or mutations, that may contribute to these disorders. To participate in this study, you must have polycythemia vera with elevated hemoglobin (higher than 18 in men and 16 in women) or thrombocytosis with an elevated platelet count (higher than 450,000). This study takes place in Salt Lake City, Utah.

The goal of the study is to look at the relationship between how individuals with Sarcoidosis take the sarcoidosis medicines and how it affects the disease, to evaluate any factors that may make individuals not want to take the medicines, and to develop and refine ways to help support individuals with Sarcoidosis especially when it comes to the medicines. The overall hypothesis is higher medication adherence will be associated with better clinical outcomes in sarcoidosis. The investigators will enroll 150 patients with biopsy proven pulmonary sarcoidosis for at least one year who are on any oral treatment regimen for at least six months into a 12-month longitudinal study.